


Risperidone

Chemical Properties

CAS No. :	359625-79-9
Formula:	C ₂₂ H ₂₃ FN ₂ O ₂
Molecular Weight:	366.43
Storage:	Powder: -20°C for 3 years Actual storage temperature shall be subject to the COA.



Biological Description

Description	Risperidone (CYR-101), a novel cyclic amide derivative, exhibits high equipotent affinities for 5-HT _{2A} and σ ₂ receptors with K _i values of 7.53 nM and 8.19 nM, respectively.
Targets(IC ₅₀)	5-HT Receptor, Sigma receptor
In vitro	Risperidone shows binding affinity for α ₁ -adrenergic receptors. Which low or no affinity for muscarinic, cholinergic, and histaminergic receptors. Although Risperidone (CYR-101) has no affinities for pre- or postsynaptic dopaminergic receptors, it is probable that sigma-2 receptors are implicated in the modulation of dopamine and glutamatergic pathways and in calcium neuronal modulation[1].

Solubility Information

Solubility	H ₂ O: < 0.1 mg/mL (insoluble), DMSO: 33.33 mg/mL (90.96 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (6.82 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.729 mL	13.6452 mL	27.2903 mL
5 mM	0.5458 mL	2.729 mL	5.4581 mL
10 mM	0.2729 mL	1.3645 mL	2.729 mL
50 mM	0.0546 mL	0.2729 mL	0.5458 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Davidson M, et al. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 Jul 28:appiajp201717010122.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481